Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.
- World-class execution – leveraging fully integrated teams – across disease biology, gene therapy vector design, translational sciences, process and analytical development, in-house GMP manufacturing and clinical research.
- State-of-the-art GMP facilities.
- World-class and proven team in gene therapy R&D, having been in leading roles or as founders for some of the most successful and innovative gene therapy and gene editing products and companies.
- Early access to clinical data made possible by Frontera’s unique scientific model.
Pipeline
Product development in gene therapy has historically focused on a limited number of rare monogenic disorders. The possibilities for gene therapy, however, are vastly greater. Frontera is realizing this potential with a pipeline that spans across not only orphan diseases, but also in larger patient markets – including Ophthalmology, Hematology, Cardiovascular and Metabolic Diseases.
World-Class R&D Team
Frontera's elite R&D team is made up of founders and scientific advisors from some of the most successful gene therapy development organizations around the world, bringing together the most advanced thinking in gene therapy, translational research, and biomanufacturing.
Scientific Advisory Board
Philip Reilly, Ph.D.
Glenn Pierce, Ph.D.
Robert Kotin, Ph.D.
Fraser Wright, Ph.D.
George Church, Ph.D.
Jean Bennett, M.D., Ph.D.
Mark Kay, M.D., Ph.D.
Xandra Breakefield, Ph.D.
Board of Directors
Wei Li, Ph.D.
Chairman, Founding Partner of Creacion Ventures
Carl Gordon, Ph.D.
Managing Partner, OrbiMed Advisors
David Wang, M.D., Ph.D.
Partner, OrbiMed Advisors
Ching Zhu, Ph.D.
Founding Partner of Creacion Ventures
Xinyan Li, Ph.D.
Co-Founder & CEO
Yanling Cao
Partner, Boyu Capital
Jiang Han
Managing Director, Sequoia Capital China
Management Team
The Frontera leadership team has broad experience from their previous leadership roles in global pharmaceutical companies as well as innovative biotech startups. The teams’ expertise spans from translational research and development of gene therapy products and biologics, GLP TOX studies, chemistry, manufacturing and Controls (CMC), clinical trial design and management, business development, new drug registration and commercialization.
Xinyan Li, Ph.D.
Co-Founder & CEO
Robert Lu, Ph.D.
Founder & Sr. VP of Technical Operations
Allison Jia
VP of Finance
Investors
Recent News
Expanded Access Policy
We are committed to developing high quality and affordable gene therapies as quickly as possible. Currently, Access to our investigational medicines is only through participation in clinical trials. Frontera is not able to offer expanded access to its investigational medicines. Find information on currently enrolling clinical trials for Frontera’s investigational therapies on clinicaltrials.gov. Frontera reserves the […]
Read MoreFDA Clears Frontera’s FT-002 for Phase II Clinical Trials in the U.S.
Boston, MA, September 23, 2024 – Frontera is excited to announce that its gene therapy product, FT-002, has been cleared by the U.S. Food and Drug Administration (FDA) for Phase II clinical trials in the U.S. This approval marks a major milestone, as FT-002 becomes the first recombinant adeno-associated virus (rAAV) gene therapy to receive […]
Read More2024 Highlights of the 5th Gene Therapy for Ophthalmic Disorders Summit: Frontera’s AAV Capsids for Suprachoroidal Delivery
Sep 10-12, 2024— the 5th Annual Gene Therapy for Ophthalmic Disorders Summit was held in Boston, USA. Dr. Zhong-Dong Shi, Executive Director, head of R&D, Frontera Therapeutics, was invited to participate in discussion on “Optimizing Capsid Design & Vector Engineering for Ophthalmic Gene Therapy” and gave a keynote address on “Novel AAV Capsids for Suprachoroidal Delivery”. […]
Read MoreFrontera Therapeutics’s Quality Control for rAAV Gene Therapy Products Presented at the 23rd China Biological Products Annual Conference 2024
May 16-18, 2024— the 23rd China Biological Products Annual Conference was held in Guangzhou, China. Dr. Li Aiqun, Director of QC, Frontera Therapeutics, was invited to participate in the symposium of “Immune Cells, Stem Cells and Gene Therapy” and focused on “Quality Control of rAAV Gene Therapy Products: Challenges of Next Generation Sequencing and Residual DNA […]
Read MoreFrontera Therapeutics Unveils Preliminary Clinical Results for FT-002 Injection at Retinal Cell and Gene Therapy Innovation Summit 2024
May 6, 2024–Frontera Therapeutics is pleased to announce significant advancements in our clinical study of FT-002, presented at Retinal Cell and Gene Therapy Innovation Summitin the United States on May 3, 2024. Professor Sui Ruifang, from Peking Union Medical College Hospital, was invited to present the clinical results, titled “Preliminary safety and efficacy of an […]
Read MoreFrontera Therapeutics to Showcase at the International Conferences in May 2024
Boston, MA, USA – April 22, 2024. Frontera Therapeutics is excited to announce its participation in several esteemed conferences in May 2024, where it will present groundbreaking research across multiple therapeutic areas, including ophthalmology, blood and cardiovascular diseases. The conferences are the 2024 Retinal Cell and Gene Therapy Innovation Summit, the 2024 American Ophthalmology Congress, […]
Read MoreFrontera’s “Innovative Solutions of rAAV Purification Process” Unveiled at the 7th Gene Therapy for Rare Disorder 2024
Boston, MA, USA – April 1, 2024. The 7th Gene Therapy for Rare Disorder 2024 took place in Boston, MA from March 26 to 29, 2024. Dr. Hongxiang Lu, Senior Vice President of Frontera Therapeutics, was invited to participate in the panel discussion on “Gene Drug Manufacturing” and gave a keynote presentation on “Case Studies […]
Read MoreFrontera’s Study Report on ” Case Studies of Resolving rAAV Aggregation & Removing Empty Vectors ” will be presented in Gene Therapy for Rare Disorders 2024
Boston, USA – March 18, 2024 – Frontera Therapeutics, a leading biotechnology company committed to advancing gene therapy drugs to address unmet medical needs worldwide, is delighted to announce its participation in the upcoming 7th Gene Therapy for Rare Disorders 2024 Conference in Boston, USA. Dr. Robert Lu, Senior Vice President of Frontera, has been […]
Read MoreFrontera Therapeutics’ FT-002 Achieves Orphan Drug Designation from the U.S. FDA for Inherited Retinal Dystrophies
BEDFORD, Mass., and Suzhou, China, January 23, 2024 — Frontera Therapeutics announces that its pioneering AAV gene therapy product, FT-002, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Inherited Retinal Dystrophies (IRD) caused by RPGR gene variants. About Orphan Drug Designation Orphan Drug Designation, granted […]
Read MorePreliminary Clinical Study Results of Frontera Therapeutics FT-002 Injection Presented at APVRS Congress
Hongkong, China, Decemeber 8th, 2023 – Preliminary clinical study results of FT-002, an AAV gene therapy treatment of Frontera Therapeutics, a potential first in class therapy for the treatment of XLRP, were reported at the 16th Asia-Pacific Vitreo-Retina Society, APVRS, 2023). Professor Sui Ruifang from Peking Union Medical College Hospital was invited to participate in […]
Read More